#IMS24RF - Twitter Hashtag

almost 2 years ago

Anitocel presented 40 enrolled and 38 dosed. 100M cells. Prior LOT 5-4. ORR 100% 76% CR or better, across all groups. Median PFS not reached at 2 years. Not even in EMD group. No clear HR genetics influence ORR. No MNT. iMMagjne-3 trial similar to CARTITUDE-4 #IMS24RF #mmsm

1

28

14

5

3K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 2 years ago

Durcabtagene highly active but has significant CRS. High response rate #IMS24RF #mmsm

0

3

1

2

891

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 2 years ago

Allí CART are active for RR MM. Small numbers in Cohort C (n=23) but intriguing. #IMS24RF #mmsm

1

6

2

1

976

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 2 years ago

@mvmateos provided data on OS for CARTITUDE 4. Also maintains PFS advantage. No new cases of MNT or cranial nerve palsies. High rate of MRD- #IMS24RF #mmsm

Rfonsi1's tweet photo. @mvmateos provided data on OS for CARTITUDE 4. Also maintains PFS advantage. No new cases of MNT or cranial nerve palsies. High rate of MRD-
#IMS24RF #mmsm https://t.co/3ftvhK1kaZ

0

15

4

8

1K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 2 years ago

Dr. @PerrotAurore presenting MIDAS trial. Incorporates MRD testing for the various pathways. MRD adapted consolidation and maintenance. Induction IsaKRD. Med age 59 yrs. #IMS24RF #mmsm

Rfonsi1's tweet photo. Dr. @PerrotAurore presenting MIDAS trial. Incorporates MRD testing for the various pathways. MRD adapted consolidation and maintenance. Induction IsaKRD. Med age 59 yrs.
#IMS24RF #mmsm https://t.co/uATk9CYhna

1

27

11

14

4K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 2 years ago

Converting to MRD clearly a good goal. And in MM much easier to justify if this occurs because of Dara addition. #IMS24RF #mmsm Congrats to the team!

1

16

4

2

1K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 2 years ago

AURIGA - DaraR vs R alone in MRD+ post SCT and CD38 naive. Primary endpoint conversion to MRD neg. Slightly more HR markers in DR arm. P53 14 vs 3%. Primary endpoint 50.5 vs 18.8 % #IMS24RF #mmsm

Rfonsi1's tweet photo. AURIGA - DaraR vs R alone in MRD+ post SCT and CD38 naive. Primary endpoint conversion to MRD neg. Slightly more HR markers in DR arm. P53 14 vs 3%. Primary endpoint 50.5 vs 18.8 %
#IMS24RF #mmsm https://t.co/hrCV9mnBBb

2

50

13

12

4K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 2 years ago

CEPHEUS trial- DaraVRD vs VRD for ND TIE MM (also deferred). Median age 70 MRD 10-5 60.9 vs 39.4%, 46.2% vs 27.3% at 10-6. 54 mos PS 68.1% vs 49.5%. Congrats to @szusmani and J&J. Exposure adjusted deaths similar to PN 55.8%, mostly grade 2 and up. QOL same #IMS24RF #mmsm

1

28

6

5

2K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 2 years ago

Attrition data from the French. #IMS24RF #mmsm

0

30

5

11

3K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 2 years ago

BMS-986393 GORC5D CART. RP2D 150 million cells, ORR 96% CR 42% ~30 on target off rumor but most were mild and resolved. Dysgeusia 29%. Peak transgéne level 14 days #IMS24RF #mmsm

Rfonsi1's tweet photo. BMS-986393 GORC5D CART. RP2D 150 million cells, ORR 96% CR 42% ~30 on target off rumor but most were mild and resolved. Dysgeusia 29%. Peak transgéne level 14 days
#IMS24RF #mmsm https://t.co/oMn75FZj5L

0

14

7

4

2K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 2 years ago

Excellent efficacy of Tal-Dara-Pom, with ORR 75-100%. Toxicity as expected. 3 or more prior lines. #IMS24RF #mmsm

1

56

15

13

5K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

about 2 years ago

Isa-KRD 4 yr FU for HR-ND MM, GMMG-CONCEPT study. 40% have del17. MRD NEG 83.5% in TE and 69.2% TIE. mPFS not reached yet. #IMS24RF #mmsm

1

27

7

2K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

about 2 years ago

PERSEUS by cytogenetic risk. All subsets benefit but greater in standard risk. A reminder that if something is good the benefit will be maximal in not high risk patients. PFS for std risk is quite impressive for dara arm. #IMS24RF #mmsm

0

19

3

2K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

about 2 years ago

CASSIOPEIA update MRD post consolidation MRD negative superior and PFS follows 72 mos 67%. MRD status mot important 77% (Dara pre/post) 70.7, 70.9 vs 51% (no Dara) negativity. Bottom line, while lots of caveats daratumumab is better > higher MRD negativity #IMS24RF #mmsm

1

18

6

3

2K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

about 2 years ago

Bela-VRD in ND TE MM. Includes consolidation. N=50. 91% MRD by flow after one year. Looks good but hard to know without directly comparing to daratumumab. Is it worth the risk of keratopathy? #IMS24RF #mmsm

4

26

6

5

4K

Top Tweets for #IMS24RF

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users